Big pharma companies with generic divisions — such as Sun Pharma, Cipla and Lupin — will have to reduce MRP. Source: Pharma Inc agrees to
NPPA said it considered the view that unviability of these formulations should not lead to a situation where these drugs become unavailable in the market and that the public is forced to switch to costly alternatives
Corporate Law Group © 2021
As per the rules of the Bar Council of India, we are not permitted to solicit work and advertise. By clicking on the “I agree” below, the user acknowledges the following:
there has been no advertisement, personal communication, solicitation, invitation or inducement of any sort whatsoever from us or any of our members to solicit any work through this website;
The user wishes to gain more information about us for his/her own information and use;
the information about us is provided to the user only on his/her specific request and any information obtained or materials downloaded from this website is completely at the user’s volition and any transmission. The information provided under this website is solely available at your request for informational purposes only, should not be interpreted as soliciting or advertisement.